Orange Book product · Brand (NDA)
EZALLOR SPRINKLE
ROSUVASTATIN CALCIUM
At a glance
Dec 18, 2018
Approved
Brand (NDA)
Application
Not listed
TE code
1
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Dec 18, 2018
7 yr 7 mo ago
Today
Patent 10413543 expires
Listed drug product patent expiration.
Feb 12, 2036
in 9 yr 10 mo
Pharmaceutical detail
Active ingredient
ROSUVASTATIN CALCIUM
Strength
EQ 5MG BASE
Dosage form
CAPSULE
Route
ORAL
TE code
Not listed
Application
NDA 208647
Product number
001
Marketing status
DISCN
Reference listed drug (RLD)
Yes
Reference standard (RS)
No
Active-ingredient family
View full familyThis is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.
- 2003CRESTORBrand (NDA)
NDA 021366 · ASTRAZENECA
- 2025ROSUVASTATIN CALCIUMGeneric (ANDA)
ANDA 206603 · MANKIND PHARMA
- 2024ROSUVASTATIN CALCIUMGeneric (ANDA)
ANDA 207296 · MACLEODS PHARMS LTD
- 2021ROSUVASTATIN CALCIUMGeneric (ANDA)
ANDA 207653 · INVENTIA
- 2020ROSUVASTATIN CALCIUMGeneric (ANDA)
ANDA 210667 · SUNSHINE
- 2019ROSUVASTATIN CALCIUMGeneric (ANDA)
ANDA 212059 · ZHEJIANG YONGTAI
- 2019ROSUVASTATIN CALCIUMGeneric (ANDA)
ANDA 207375 · SHANDONG
- 2019ROSUVASTATIN CALCIUMGeneric (ANDA)
ANDA 206381 · SCIEGEN PHARMS
- 2019ROSUVASTATIN CALCIUMGeneric (ANDA)
ANDA 207626 · UMEDICA
- 2019ROSUVASTATIN CALCIUMGeneric (ANDA)
ANDA 206513 · ZHEJIANG JINGXIN
- 2018ROSUVASTATIN CALCIUMGeneric (ANDA)
ANDA 208850 · AMNEAL PHARMS CO
- 2017ROSUVASTATIN CALCIUMGeneric (ANDA)
ANDA 208898 · MSN
Listed patents (1)
| Patent | Expires | In | Type |
|---|---|---|---|
| 10413543 | Feb 12, 2036 | in 9 yr 10 mo | Product |

